Skip to main content
NVO
NYSE Life Sciences

Novo Nordisk's CagriSema Misses Primary Endpoint in Head-to-Head Obesity Trial Against Tirzepatide

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$40.45
Mkt Cap
$210.411B
52W Low
$43.08
52W High
$93.8
52W Position info
6.1% below low
Off High info
57% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

NVO is trading near its 52-week low of $43.08 (6.1% below the low).

Summary

Novo Nordisk announced that its experimental obesity drug, CagriSema, failed to demonstrate non-inferiority against tirzepatide in the REDEFINE 4 Phase 3 trial, despite achieving significant weight loss.


Key Events · Product Development and Regulatory · NVO

  • CagriSema Misses Primary Endpoint

    The REDEFINE 4 Phase 3 trial for CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) did not achieve its primary endpoint of non-inferiority on weight loss compared to tirzepatide 15 mg after 84 weeks.

  • Significant Weight Loss Achieved

    CagriSema demonstrated a 23.0% weight loss after 84 weeks, which the company noted as a positive outcome, but this was less than the 25.5% achieved by tirzepatide in the head-to-head comparison.

  • Competitive Implications

    The failure to show non-inferiority against a leading competitor like tirzepatide could hinder CagriSema's competitive standing in the rapidly evolving obesity treatment market.

  • Future Development Plans

    Novo Nordisk plans to explore the full weight loss potential of CagriSema through additional trials, including a higher-dose combination trial planned for the second half of 2026, and awaits an FDA decision on earlier trials by late 2026.


Analysis · NVO · Life Sciences

Novo Nordisk's CagriSema, a key pipeline asset in the highly competitive obesity market, failed to meet its primary endpoint of non-inferiority against tirzepatide in the REDEFINE 4 Phase 3 trial. While CagriSema demonstrated a significant 23% weight loss, this was less than the 25.5% achieved by tirzepatide. This outcome suggests a competitive disadvantage for CagriSema against a leading rival, potentially impacting its future market positioning and sales projections. Investors should monitor the results of ongoing and planned higher-dose trials to assess the drug's full potential and competitive viability.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NVO was trading at $40.45 on NYSE in the Life Sciences sector, with a market capitalization of approximately $210.4B. The 52-week trading range was $43.08 to $93.80. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NVO - Latest Insights

NVO
Nov 04, 2026, 8:35 AM EST
Source: Benzinga
Importance Score:
8
Price at Filing: $42.91
Real-time Price: $39.60 info
Change: -$3.30 (-8%) info
Market Cap: $176.163B info
NVO
Nov 04, 2026, 7:47 AM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $42.90
Real-time Price: $39.60 info
Change: -$3.30 (-8%) info
Market Cap: $176.163B info
NVO
Nov 04, 2026, 4:00 AM EST
Source: Seeking Alpha
Importance Score:
9
Price at Filing: $41.96
Real-time Price: $39.60 info
Change: -$2.36 (-6%) info
Market Cap: $176.163B info
NVO
Oct 27, 2026, 3:10 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $39.16
Real-time Price: $39.60 info
Change: +$0.440 (+1%) info
Market Cap: $176.163B info
NVO
Oct 02, 2026, 5:53 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $36.88
Real-time Price: $39.60 info
Change: +$2.72 (+7%) info
Market Cap: $176.163B info